UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report: February 24, 2006

Date of earliest event reported: February 23, 2006

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other Jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the obligation of the registrant under any of the

following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17

CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17

CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 1.01

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On February 23, 2006, the Compensation Committee of the Board of Directors

of Pfizer Inc. (the "Company") approved, and the independent Directors

ratified, the annual base salaries, annual incentive (i.e. cash bonus) awards,

stock option grants, restricted stock unit grants, performance share grants

for the period January 1, 2006 to December 31, 2008 and payment of previously

awarded performance-contingent share award grants for the periods ending December

31, 2005 for the Named Executive Officers in our 2006 Proxy Statement. The salary

information is effective as of April 1, 2006. Also on February 23, 2006, the

Compensation Committee of the Board of Directors of Pfizer Inc., approved, and

the independent Directors ratified, changes to the Executive Change in Control

Severance Agreements for the Named Executive Officers and the Board of Directors

approved changes to the compensation program for non-employee Directors.

Salary and Cash Bonus

The Compensation Committee authorized the payment of annual bonus awards to

each of the Company's Named Executive Officers for the year ended December 31,

2005 under the Pfizer Inc. Executive Annual Incentive Plan. The Plan is intended

to ensure the tax deductibility of the bonus for the Company. The maximum individual

annual bonus under this plan is 0.3% (three tenths of one percent) of Adjusted

Net Income. The Plan defines "Adjusted Net Income" to mean income

before cumulative effect of accounting changes as shown on the audited Consolidated

Statement of Income of the Company. If income before cumulative effect of accounting

changes is not shown on the Statement, then Adjusted Net Income will mean net

income as shown on the Statement. The annual incentive awards, shown on the

table below, were made within the maximum established under the Plan and were

based on the Committee's assessment of the Company's and each executive's performance

measured against previously set financial and strategic objectives. This assessment

included a review of significant accomplishments and business performance in

a challenging and dynamic environment, as well as stock price performance during

2005.

The following table sets forth the annual base salaries as of April of each

year and the cash bonus amounts for 2005 (which were awarded in February 2006)

and for 2004 (which were awarded in February 2005) for Henry A. McKinnell, Karen

Katen, David L. Shedlarz, Jeffrey B. Kindler and John L. LaMattina, who will

be included as the Named Executive Officers in the Company's 2006 Proxy Statement.

Please note that any changes to base salaries do not become effective until

April of each year.

Name and Position

Salary Effective Date

Base Salary ($)

Performance Year for Bonus

Bonus ($)

Dr. McKinnell

April 2006

2,270,500

2005

3,700,000

Chairman and CEO

April 2005

2,270,500

2004

3,986,300

Ms.Katen

April 2006

1,235,000

2005

1,535,600

Vice Chairman and President - Pfizer Human Health

April 2005

1,176,200

2004

1,274,100

Mr. Shedlarz

April 2006

1,016,600

2005

1,088,000

Vice Chairman

April 2005

983,100

2004

1,005,200

Mr. Kindler

April 2006

947,500

2005

1,000,000

Vice Chairman and General Counsel

April 2005

902,200

2004

869,600

Dr. LaMattina

April 2006

885,200

2005

787,300

Senior V.P. and President - Pfizer Global Research and

Development

April 2005

837,500

2004

705,200

Long-Term Incentive Award Payments

The Compensation Committee also authorized payments to the Company's Named Executive

Officers of long-term incentive awards which were previously granted. These

payments were based on the performance of Pfizer versus our peer group companies

with respect to both total shareholder return and earnings per share.

The following table sets forth the long-term incentive payouts for the performance

periods ended December 31, 2005 (which are paid in February, 2006) and December

31, 2004 (which were paid in February, 2005) made to the Company's Named Executive

Officers under the 2001 Performance-Contingent Share Award Plan or the previous

Performance-Contingent Share Award Program. The 2001 Performance-Contingent

Share Award Plan has been replaced by the Pfizer Inc. 2004 Stock Plan for awards

with performance periods beginning on January 1, 2005 and later. Receipt of

performance shares awarded under the current Plan and the previous Plan and

Program may be deferred.

Name

Performance Period

Shares Earned (#)

Value ($)

Dr. McKinnell

1/1/01 - 12/31/05

210,000

5,489,400

1/1/00 - 12/31/04

220,800

5,829,120

Ms.Katen

1/1/01 - 12/31/05

127,260

3,326,576

1/1/00 - 12/31/04

125,280

3,307,392

Mr. Shedlarz

1/1/01 - 12/31/05

88,620

2,316,527

1/1/00 - 12/31/04

95,520

2,521,728

Mr. Kindler

1/1/02 - 12/31/05

39,840

1,041,418

1/1/02 - 12/31/04

49,980

1,319,472

Dr. LaMattina

1/1/01 - 12/31/05

62,370

1,630,352

1/1/00 - 12/31/04

61,440

1,622,016

Stock Option, Restricted Stock Unit and Performance Share Grants

In addition, the Committee approved grants of ten-year non-qualified stock

options, restricted stock units and performance shares to each of the Named

Executive Officers pursuant to the Pfizer Inc. 2004 Stock Plan.

The following table sets forth information regarding stock options granted to

the Named Executive Officers in 2006 and 2005.

Name

Year

Number of Stock Options (1)

Exercise Price

Dr. McKinnell

2006

880,000

$26.20

2005

880,000

$26.20

Ms.Katen

2006

500,000

$26.20

2005

371,000

$26.20

Mr. Shedlarz

2006

400,000

$26.20

2005

301,000

$26.20

Mr. Kindler

2006

400,000

$26.20

2005

261,000

$26.20

Dr. LaMattina

2006

300,000

$26.20

2005

219,500

$26.20

(1) The 2006 stock options vest on February 23, 2009, the third anniversary

of the grant, subject to continuous employment. The 2005 stock options vest

in three equal annual installments beginning on the third anniversary of the

date of grant, subject to continuous employment.

The following table sets forth information regarding restricted stock units

granted to the Named Executive Officers in 2005 and 2006.

Name

Year

Number of Restricted Stock Units(#)

Dollar Value ($) (1)

Dr. McKinnell

2006

89,180

2,331,165

2005

Ms.Katen

2006

47,470

1,240,866

2005

Mr. Shedlarz

2006

31,650

827,331

2005

Mr. Kindler

2006

27,690

723,817

2005

Dr. LaMattina

2006

23,070

603,050

2005

(1) The dollar values shown above are based on the closing price of Pfizer's

common stock ($26.14) on February 23, 2006. These restricted stock unit awards

vest on February 23, 2009. Dividends on these restricted stock units are reinvested

in Pfizer common stock units.

Effective February 23, 2006, the Compensation Committee adopted the Executive

Long-Term Incentive Program. This program consists of stock options and restricted

stock units, as shown above, as well as performance shares. The following table

sets forth information concerning the participation of the Named Executive Officers

in the performance share portion of the Executive Long-Term Incentive Program

for the performance period January 1, 2006 to December 31, 2008 (as well as

for the January 1, 2005 to December 31, 2009 performance period under the previous

2001 Performance-Contingent Share Award Plan). Under the 2006 program, the Named

Executive Officers were awarded the right to earn shares of our common stock.

Actual payouts of these shares, if any, will be determined by a non-discretionary

formula, which measures our performance over a three-year period using total

shareholder return (including reinvestment of dividends) ( TSR ),

measured over the performance period relative to the industry peer group. If

our minimum TSR performance is below the threshold level relative to the peer

group, then no shares will be earned. If our TSR over the performance period

is above the threshold level relative to the peer group but is negative, then

the payout will be no greater than the target award. To the extent the Company's

performance exceeds the threshold performance level relative to the peer group

and is positive, a varying amount of shares of common stock up to the maximum

will be earned as follows:

Pfizer's Relative Performance

Payout

as a % of Target

1 (highest)

200%

200%

175%

150%

125%

100%

75%

50%

25%

10

0%

11 (lowest)

0%

Estimated Future Payouts -

Performance Shares

Name

Number of Shares (1)

Performance Period (or Other Period Until Maturation or Payment)

Threshold (#) (2)

Target (#)

Maximum (#)

Dr. McKinnell

1/1/06 - 12/31/08

22,295

89,180

178,360

1/1/05 - 12/31/09

28,820

172,920

288,200

Ms.Katen

1/1/06 - 12/31/08

11,868

47,470

94,940

1/1/05 - 12/31/09

13,889

83,330

138,890

Mr. Shedlarz

1/1/06 - 12/31/08

7,913

31,650

63,300

1/1/05 - 12/31/09

11,112

66,670

111,120

Mr. Kindler

1/1/06 - 12/31/08

6,923

27,690

55,380

1/1/05 - 12/31/09

9,722

58,330

97,220

Dr. LaMattina

1/1/06 - 12/31/08

5,768

23,070

46,140

1/1/05 - 12/31/09

8,333

50,000

83,330

(1) The actual number of shares that will be paid out at the end of the performance

period, if any, cannot be determined because the shares earned by the Named

Executive Officers will be based upon our future performance compared to the

future performance of the peer group, but will be set forth in a subsequent

Form 8-K filed with the SEC.

(2) If our performance is below the threshold level relative to the peer group,

then no shares will be earned. To the extent the Company's performance exceeds

the threshold performance level relative to the peer group, a varying amount

of shares of common stock up to the maximum will be earned.

Amendment to Executive Change-in-Control Severance Agreements for Named Executive

Officers

On February 23, 2006, the Compensation Committee approved an amendment to the

Change-in-Control Severance Agreements for the Named Executive Officers that

had been voluntarily agreed to in writing by the Named Executive Officers. The

amendment provides that, if the Named Executive Officer is terminated by the

Company without Cause or by the executive for Good Reason following a Change

in Control of the Company, amounts in respect of outstanding performance-contingent

share awards (or any successor long-term compensation plan or award in effect

as of the date of such termination) shall be determined and paid based on the

target number of shares that the executive could have received pursuant to all

such outstanding awards. Prior to this amendment, such Agreements provided that

such payments would be based on the maximum, instead of the target, number of

shares that the executive could have received.

The Company intends to provide additional information regarding the compensation

awarded to the Named Executive Officers in respect of and during the year ended

December 31, 2005, in the 2006 Proxy Statement, which is expected to be filed

with the Securities and Exchange Commission on or about March 16, 2006.

Compensation of Non-Employee Directors

Effective March 1, 2006, the compensation for non-employee Directors has been

modified to eliminate meeting fees and Committee retainers and consists solely

of the following:

an annual retainer of $75,000; and

an award of 5,000 Pfizer stock units to each Director upon joining

the Board and to each Director upon election at each Annual Meeting of Shareholders.

If a Director attends less that 80% of Board and Committee meetings in a year,

the Director s annual retainer will be pro-rated.

In addition, the Chairs of Board Committees and the Lead Independent Director

will receive annual retainers as follows:

Capacity

Chairs of Compensation and Corporate Governance Committees

Chair of Audit Committee

Lead Independent Director and Chair of Science & Technology

Committee

Retainer

$15,000

$20,000

$25,000

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

Margaret M. Foran

Title: Senior Vice President-Corporate

Governance, Associate General Counsel and Corporate Secretary

Dated: February 24, 2006